MAPT and Alzheimer disease: Previous studies have found that neocortical tau PET tracer uptake is higher in younger individuals with AD [39, 40], further highlighting that tau368/t-tau is captures an aspect of tau pathology not well-reflected using only core CSF biomarkers.